MEDIUM confidence: 100% data completeness, but the composite (52) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $31.7B— | $31.2B-1.4% | $32.4B+3.6% | $33.5B+3.6% | $36.4B+8.4% |
| EPS (dil.) | $3.73— | $2.82-24.4% | $2.76-2.1% | $3.61+30.8% | $3.73+3.3% |
| Free Cash Flow | $6.0B— | $4.6B-23.4% | $5.2B+13.5% | $5.2B-0.3% | $5.4B+4.6% |
| Gross Margin | 68.0% | 65.7%-2.3pp | 65.3%-0.3pp | 65.3%-0.0pp | 65.0%-0.3pp |
| Operating Margin | 18.2% | 17.6%-0.6pp | 15.9%-1.7pp | 17.8%+1.9pp | 17.8%+0.0pp |
| Net Margin | 15.9% | 12.0%-3.9pp | 11.4%-0.7pp | 13.9%+2.5pp | 13.2%-0.7pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $91 avg across 15 analysts.
Buy-rated share 59% → 66% over ~3 months (+6pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $1.54 | $1.55 | +0.6% |
| Feb 2026 | $1.34 | $1.36 | +1.5% |
| Nov 2025 | $1.31 | $1.36 | +3.8% |
| Aug 2025 | $1.23 | $1.26 | +2.4% |
| May 2025 | $1.58 | $1.62 | +2.5% |
| Feb 2025 | $1.36 | $1.39 | +2.2% |
| Nov 2024 | $1.25 | $1.26 | +0.8% |
| Aug 2024 | $1.20 | $1.23 | +2.5% |
Net insider -$5.7M over 180 days (0 open-market buys, 8 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 4.6%/yr (revenue basis).
Base free cash flow $5.3B (avg FY2024–FY2026; latest year $5.4B) · equity value $117.2B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 52 for Medtronic plc suggests a neutral outlook, with the long-term and short-term scores closely aligned. The stock scores high on profitability, with a robust gross margin of 65.0% and an ROE of 9.8%, while its value score is also relatively strong, driven by a P/E of 24.4. However, growth and momentum scores are more subdued, reflecting modest revenue and EPS growth, as well as a recent surge in price that has left the stock with an RSI of 79.4, indicating overbought conditions.